KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Shares Outstanding (2016 - 2025)

Neogenomics (NEO) has disclosed Shares Outstanding for 14 consecutive years, with $127.1 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Shares Outstanding rose 1.17% year-over-year to $127.1 million, compared with a TTM value of $127.1 million through Jun 2023, up 1.17%, and an annual FY2022 reading of $126.9 million, up 2.26% over the prior year.
  • Shares Outstanding was $127.1 million for Q2 2023 at Neogenomics, roughly flat from $127.2 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $127.2 million in Q1 2023 and bottomed at $95.3 million in Q1 2019.
  • Average Shares Outstanding over 5 years is $116.2 million, with a median of $119.9 million recorded in 2021.
  • The sharpest move saw Shares Outstanding grew 27.41% in 2019, then grew 1.17% in 2023.
  • Year by year, Shares Outstanding stood at $104.8 million in 2019, then increased by 6.96% to $112.1 million in 2020, then grew by 10.74% to $124.1 million in 2021, then rose by 2.26% to $126.9 million in 2022, then grew by 0.18% to $127.1 million in 2023.
  • Business Quant data shows Shares Outstanding for NEO at $127.1 million in Q2 2023, $127.2 million in Q1 2023, and $126.9 million in Q4 2022.